AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20810171 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 31
Study 20810171 — intervention group
Group type: EXPERIMENTAL
Intervention: HSK eyes
Number of subjects: 31
Study 17953950 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of oral nimesulide
Number of subjects: 440
Study 17953950 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 440
Study 17117562 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic auricular point therapy (blood‐letting on the ear back, point injection of own blood, pricking ear point)
Number of subjects: 108
Study 17117562 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 108
Study 12594142 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 60 mg
Number of subjects: 90
Study 12594142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 15 mg
Number of subjects: 90
Study 12594142 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 10 mg
Number of subjects: 90
Study 12594142 — intervention group
Group type: COMPARATOR
Intervention: Control (Ropivacaine and Levobupivacaine)
Number of subjects: 90
Study 10976544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release nifedipine
Number of subjects: 226
Study 8833209 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral bone from patients with fractured neck of femur
Number of subjects: 0
Study 8833209 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone adjacent to joints with osteoarthrosis
Number of subjects: 0
Study 8833209 — intervention group
Group type: COMPARATOR
Intervention: Control bone (necropsy control group)
Number of subjects: 0
Study 1422322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day)
Number of subjects: 28
Study 1422322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 28
Study 4074607 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional metoprolol 200 mg
Number of subjects: 12
Study 4074607 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting metoprolol 200 mg
Number of subjects: 12
Study 4074607 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 12
Study 4074607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31420920 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin (dual COX inhibition)
Number of subjects: 0
Study 31420920 — intervention group
Group type: COMPARATOR
Intervention: Standard low-dose aspirin (selective COX-1 inhibition)
Number of subjects: 0
Study 30238727 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block combined with local infiltration anesthesia
Number of subjects: 104
Study 30238727 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative local infiltration anesthesia
Number of subjects: 104
Study 27936941 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (direct renin inhibitor)
Number of subjects: 36
Study 27936941 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II receptor blockers (ARB)
Number of subjects: 36
Study 24262929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8mg/kg
Number of subjects: 8
Study 24262929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 8
Study 24262929 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab (TCZ) 4mg/kg
Number of subjects: 8
Study 24262929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 22640229 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 50 µg
Number of subjects: 160
Study 22640229 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol 25 µg
Number of subjects: 160
Study 20656153 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating microscope angled 15 degrees nasal to the fovea (study group)
Number of subjects: 30
Study 20656153 — intervention group
Group type: COMPARATOR
Intervention: Control group with operating microscope directly overhead around the optic disc region
Number of subjects: 30
Study 18715407 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion sonography (SIS)
Number of subjects: 100
Study 18715407 — intervention group
Group type: COMPARATOR
Intervention: Office hysteroscopy
Number of subjects: 100
Study 15942186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish treatment twice a year at 6-month intervals
Number of subjects: 758
Study 15942186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish treatment 3 times a year within 1 week
Number of subjects: 758
Study 15942186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish treatment 8 times per year during semesters with 1-month intervals
Number of subjects: 758
Study 15942186 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 758
Study 15942186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish treatment once a year
Number of subjects: 758
Study 12589354 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 16
Study 12589354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride (180 mg)
Number of subjects: 16
Study 12589354 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine dihydrochloride (5 mg)
Number of subjects: 16
Study 12589354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11097583 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK surgery
Number of subjects: 58
Study 8991237 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined yellow fever and measles vaccines
Number of subjects: 0
Study 8991237 — intervention group
Group type: COMPARATOR
Intervention: Yellow fever vaccine administered separately
Number of subjects: 0
Study 8991237 — intervention group
Group type: COMPARATOR
Intervention: Measles vaccine administered separately
Number of subjects: 0
Study 1322512 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg subcutaneous sumatriptan
Number of subjects: 67
Study 1322512 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg subcutaneous sumatriptan
Number of subjects: 67
Study 1322512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 6412265 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital
Number of subjects: 0
Study 29948103 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight treatment with the occlusive intensive patch (OIP) containing Allium cepa extract and allantoin for 12-24 weeks
Number of subjects: 125
Study 29948103 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight treatment with the occlusive intensive patch (OIP)
Number of subjects: 125
Study 29948103 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject- and investigator-evaluated Global Aesthetic Improvement Scale scores for treated scars
Number of subjects: 125
Study 29948103 — intervention group
Group type: EXPERIMENTAL
Intervention: Global comfort of the OIP
Number of subjects: 125
Study 29948103 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety of the OIP
Number of subjects: 125
Study 29948103 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 125
Study 29141661 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Feedback Intervention to Promote Positive Parenting and Sensitive Discipline (VIPP-SD)
Number of subjects: 300
Study 29141661 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 300
Study 26329980 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (40-100 mg/day)
Number of subjects: 524
Study 26329980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study 24320833 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Recovery Action Planning (WRAP)
Number of subjects: 143
Study 24320833 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education course
Number of subjects: 143
Study 21436335 — intervention group
Group type: EXPERIMENTAL
Intervention: Wingspan stent placement for MCA stenosis
Number of subjects: 60
Study 21436335 — intervention group
Group type: COMPARATOR
Intervention: Wingspan stent placement for other stenosis
Number of subjects: 60
Study 18193377 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol enriched drinkable yogurt (1.6 g of free sterol equivalents)
Number of subjects: 83
Study 18193377 — intervention group
Group type: COMPARATOR
Intervention: Plain low-fat yogurt (control)
Number of subjects: 83
Study 18193377 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol enriched drinkable yogurt
Number of subjects: 83
Study 16644440 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic Doppler echocardiography (TTDE)
Number of subjects: 52
Study 14598036 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychodynamic psychotherapy
Number of subjects: 70
Study 11140432 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) administered via dry powder and metered-dose inhalers
Number of subjects: 13
Study 11140432 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP)
Number of subjects: 13
Study 8872851 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with felodipine
Number of subjects: 411
Study 8872851 — intervention group
Group type: COMPARATOR
Intervention: Low-dose felodipine
Number of subjects: 411
Study 8872851 — intervention group
Group type: COMPARATOR
Intervention: High-dose felodipine plus additional drugs
Number of subjects: 411
Study 1511150 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on sampling quality evaluation in laboratory protocols
Number of subjects: 179
Study 1511150 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific advice on indication
Number of subjects: 179
Study 1511150 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly performance overviews comparing individual doctors to peers
Number of subjects: 179
Study 1511150 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spatula and Cytobrush method
Number of subjects: 179
Study 1511150 — intervention group
Group type: EXPERIMENTAL
Intervention: Request for further information, help, or training
Number of subjects: 179
Study 6595452 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (10,000 IU daily)
Number of subjects: 13
Study 6595452 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation after switching from placebo
Number of subjects: 13
Study 6595452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30554409 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of NOx over 70 µmol/L
Number of subjects: 1869
Study 30554409 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of NOx over 70 µmol/L in men
Number of subjects: 1869
Study 29505803 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz excitatory rTMS to the rIFG at 100% motor threshold with 900 pulses per session
Number of subjects: 20
Study 29505803 — intervention group
Group type: COMPARATOR
Intervention: Sham-controlled condition
Number of subjects: 20
Study 25503483 — intervention group
Group type: EXPERIMENTAL
Intervention: Online journal writing intervention
Number of subjects: 0
Study 25503483 — intervention group
Group type: EXPERIMENTAL
Intervention: High disclosure of negative emotions during journaling
Number of subjects: 0
Study 25541919 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg every 6 hours) intravenously for fifteen days
Number of subjects: 58
Study 25541919 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 58
Study 21725375 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hospital discharge (Arm A)
Number of subjects: 131
Study 21725375 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital-based follow-up (Arm B)
Number of subjects: 131
Study 19947262 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at Shenshu (BL 23), Guanyuan (CV 4), Taixi (KI 3), Sanyinjiao (SP 6) for 12 weeks
Number of subjects: 98
Study 19947262 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Polyene Phosphatidylcholine Capsules for 12 weeks
Number of subjects: 98
Study 17537866 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg once daily for 5 days
Number of subjects: 469
Study 17537866 — intervention group
Group type: COMPARATOR
Intervention: Gemifloxacin 320 mg once daily for 7 days
Number of subjects: 469
Study 15277269 — intervention group
Group type: EXPERIMENTAL
Intervention: Study recommendations for boost radiation treatment
Number of subjects: 248
Study 15277269 — intervention group
Group type: COMPARATOR
Intervention: Stated policy for boost radiation treatment
Number of subjects: 248
Study 15277269 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive disease at a resection margin
Number of subjects: 248
Study 11455677 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated formulation containing 90 mg peppermint oil and 50 mg caraway oil (test)
Number of subjects: 16
Study 11455677 — intervention group
Group type: COMPARATOR
Intervention: Immediate release formulation containing 36 mg peppermint oil and 20 mg caraway oil (reference)
Number of subjects: 16
Study 11455677 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated formulation (test)
Number of subjects: 16
Study 11455677 — intervention group
Group type: COMPARATOR
Intervention: Immediate release formulation (reference)
Number of subjects: 16
Study 9744605 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual hyoscyamine (0.125 mg/tablet, 2 tablets)
Number of subjects: 150
Study 9744605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 8688342 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sodium cromoglycate
Number of subjects: 20
Study 8688342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2272214 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary history method
Number of subjects: 194
Study 2272214 — intervention group
Group type: COMPARATOR
Intervention: 3-day food record
Number of subjects: 194
Study 115193 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine
Number of subjects: 11
Study 115193 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 11
Study 115193 — intervention group
Group type: EXPERIMENTAL
Intervention: pimozide
Number of subjects: 11
Study 115193 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 31896122 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovations originating within the unit linked to the availability of new technology
Number of subjects: 44
Study 31896122 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of new knowledge or technology
Number of subjects: 44
Study 31896122 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines or regulations from outside the unit
Number of subjects: 44
Study 31896122 — intervention group
Group type: EXPERIMENTAL
Intervention: Need to standardize practices
Number of subjects: 44
Study 31896122 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in research
Number of subjects: 44
Study 31896122 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of adverse events
Number of subjects: 44
Study 31896122 — intervention group
Group type: EXPERIMENTAL
Intervention: Wish to improve care
Number of subjects: 44
Study 31896122 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported changes concerning ventilation, feeding and nutrition, neonatal sepsis, infant care, pain management and care of parents
Number of subjects: 44
Study 30690687 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant RT alone (n=646)
Number of subjects: 3489
Study 30690687 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant anthracycline-based CT alone (n=705)
Number of subjects: 3489
Study 30690687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined adjuvant RT and anthracycline-based CT (n=1025)
Number of subjects: 3489
Study 30690687 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n=1113)
Number of subjects: 3489
Study 26273852 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood during retrieval
Number of subjects: 0
Study 26273852 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood during encoding
Number of subjects: 0
Study 26273852 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood at both encoding and retrieval
Number of subjects: 0
Study 26273852 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood
Number of subjects: 0
Study 24043481 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 130
Study 24043481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 21679588 — intervention group
Group type: EXPERIMENTAL
Intervention: Live tissue training (animal model group)
Number of subjects: 24
Study 21679588 — intervention group
Group type: COMPARATOR
Intervention: Simulator training (simulator group)
Number of subjects: 24
Study 19220889 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research on parents' experiences of trial recruitment
Number of subjects: 0
Study 16720926 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic tropisetron
Number of subjects: 288
Study 16720926 — intervention group
Group type: COMPARATOR
Intervention: Rescue tropisetron
Number of subjects: 288
Study 15301778 — intervention group
Group type: EXPERIMENTAL
Intervention: External loads of 19 kg with antagonistic co-contraction
Number of subjects: 13
Study 15301778 — intervention group
Group type: EXPERIMENTAL
Intervention: External loads of 38 kg with antagonistic co-contraction
Number of subjects: 13
Study 15301778 — intervention group
Group type: EXPERIMENTAL
Intervention: External stiffness of 4.9 kN/m
Number of subjects: 13
Study 15301778 — intervention group
Group type: EXPERIMENTAL
Intervention: External stiffness of 8.1 kN/m
Number of subjects: 13
Study 15301778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean intrinsic stiffness
Number of subjects: 13
Study 15301778 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflex gain
Number of subjects: 13
Study 15301778 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant reflex delay
Number of subjects: 13
Study 11771442 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic assisted colectomy (LAC)
Number of subjects: 1200
Study 11771442 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 1200
Study 9103468 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (rhIL-10) 25 microg/kg administered 2 min before endotoxin challenge
Number of subjects: 16
Study 9103468 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (rhIL-10) 25 microg/kg administered 1 hour after endotoxin challenge
Number of subjects: 16
Study 9103468 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (rhIL-10) administered both before and after endotoxin challenge
Number of subjects: 16
Study 9103468 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 16
Study 1531818 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 81
Study 1531818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 2859409 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal cells (purified lymphocytes from husbands' blood)
Number of subjects: 49
Study 2859409 — intervention group
Group type: COMPARATOR
Intervention: Own cells (purified lymphocytes from their own blood)
Number of subjects: 49
Study 31358708 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-resorbable GTR membrane
Number of subjects: 20
Study 31358708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable GTR membrane
Number of subjects: 20
Study 31358708 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 28980166 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cefotaxime dosing regimens
Number of subjects: 49
Study 28980166 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cefotaxime at 100 mg·kg-1·day-1
Number of subjects: 49
Study 27566961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 56
Study 27566961 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist supportive clinical management (SSCM)
Number of subjects: 56
Study 27566961 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 56
Study 24338947 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based intervention (cognitive-behavioral therapy and/or psychopharmacology)
Number of subjects: 1004
Study 24338947 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1004
Study 22569436 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg every other day)
Number of subjects: 18
Study 22569436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21169102 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 32
Study 21169102 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control)
Number of subjects: 32
Study 17611834 — intervention group
Group type: EXPERIMENTAL
Intervention: 90‐min interval training program
Number of subjects: 12
Study 17611834 — intervention group
Group type: COMPARATOR
Intervention: Rest in sitting position for 90 min
Number of subjects: 12
Study 15675576 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU alone
Number of subjects: 0
Study 15675576 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU+cisplatin
Number of subjects: 0
Study 15675576 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer agents (TS‐1, CPT‐11, docetaxel, paclitaxel)
Number of subjects: 0
Study 15675576 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11 and paclitaxel-based regimens
Number of subjects: 0
Study 12386077 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 25
Study 12386077 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 25
Study 12386077 — intervention group
Group type: COMPARATOR
Intervention: Control (Lubricant)
Number of subjects: 25
Study 10445304 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 178